Lyme Disease Vaccine Trial Found Safe for Children
A new four-dose vaccine study suggests a potential preventive option for children aged 5 to 17 against Lyme disease.
Updated on Oct. 12, 2026 in Children’s Health
Live Poll
If approved, would you vaccinate your children against Lyme disease?
A phase 3 clinical trial of 3,547 children across the United States has shown that a new four-dose vaccine is safe and tolerable. This development marks a potential path toward renewed prevention strategies for young people at risk of Lyme disease.
Why it matters
The vaccine works by targeting the OspA protein on Borrelia burgdorferi bacteria, which may eventually provide a vital tool for preventing infection. This study comes as experts continue to refine approaches to protect children from tick-borne illness.
In a phase 3 trial involving 3,547 participants aged 5 to 17 across 57 U.S. sites, researchers found the vaccine safe with serious adverse events occurring in 1.6% of both the vaccine and placebo groups. The study evaluated a four-dose series administered over an 18-month period.
The players
FDA
The federal agency responsible for evaluating the safety and efficacy of new vaccines prior to market authorization.
The details
The experimental vaccine, known as LB6V, uses six serotypes of the OspA protein to trigger the production of protective antibodies. These antibodies circulate in the blood and enter a tick during feeding, where they neutralize the Borrelia burgdorferi bacteria responsible for Lyme disease before transmission can occur. The four-dose regimen follows a schedule at baseline, 2 months, 6 months, and 18 months.
Timeline
1998 saw the initial approval of the LYMErix vaccine.
2002 was the year LYMErix was pulled from the market.
December 2022 marked the start of participant enrollment.
July 2025 signaled the conclusion of participant enrollment.
Health Landscape
The current trial marks a significant milestone in vaccine development, emerging as a successor to the historical path established by the 2002 withdrawal of the LYMErix vaccine. Researchers are now navigating the rigorous safety and efficacy standards required for modern tick-borne disease prevention.
While this trial shows promise, the vaccine is not yet available and its use will ultimately depend on future licensing decisions by the FDA. Families should continue to focus on standard tick-avoidance measures and discuss current prevention guidelines with a pediatrician.
The takeaway
This phase 3 trial reinforces the potential for a new pediatric Lyme disease vaccine to meet rigorous safety benchmarks. Residents should maintain focus on proven tick-avoidance strategies and speak with a doctor about individual risk factors for tick-borne diseases.
Further reading
Learn more about evolving pediatric prevention strategies in our Children’s Health section.
Source note: This article includes information reported by Medscape.
Live Poll
If approved, would you vaccinate your children against Lyme disease?
